Evercyte and VTU Launch Recombinant Media Supplement
The companies have launched VEGF 165, their first joint product for cell culture applications.
Evercyte GMbH and VTU Technology have entered into a collaboration agreement on the development of recombinant media supplements for cell culture applications and launched their first conjointly developed recombinant product, according to a May 24, 2016 press announcement. Vascular Endothelial Growth Factor 165 (VEGF 165), the company’s newly released product, is a growth factor with physiological and clinical relevance used in diverse biological in-vitro tests.
The Evercyte and VTU collaboration will allow the companies to develop recombinant media supplements, including growth factors and cytokines. Recombinant products will be produced by VTU based on its proprietary Pichia technology, facilitating the manufacturing of media supplements.
Source: Evercyte
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
